Legacy AI grade · Sources dated 2026-06-08. Not expert reviewed. Coverage is limited to the listed sources. About the new summary workflow

Chondroitin for Skin Aging

Verdict: Insufficient Evidence

Across 3 PubMed studies, the evidence for Chondroitin in Skin Aging grades Tier U — unverified / insufficient. Research is still too limited to draw a firm conclusion.

U ⚫ U Unverified Insufficient Evidence

🔬Why this grade7-layer evidence engine

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable

Raw score 0.41

← counter-evidence / ineffectiveeffective / strong evidence →

Final grade

U · Insufficient Evidence

Confidence

71%

Broadly consistent

Evidence level

35821992 is longevity drug-screening SR not skin MA

How strongly each layer supports this effect

lower = less supportive

L11 AI re-checkIndependent read

0.20

L2 PubMedPrimary literature

0.40

L3 MechanismPlausibility

0.45

L1 ExamineGlobal benchmark

0.50

L5 Clinical bodiesAuthoritative stance

0.50

Against Mixed Supports

▸View the full decision path (audit trail)

compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.406
tier_from_score — 依分數區間映射至 tier letter
apply_hec_rules — 無高階證據可裁決
tier_strict_requirement_check — Tier 條件達標，未降階
detect_disputes — 偵測到 0 個 hard + 1 個 soft dispute
decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (3)L2 · primary research & systematic reviews

Daily oral supplementation with collagen peptides combined with vitamins and other bioactive compounds improves skin elasti

PMID: 30122200 2018 RCT (multi-ingredient collagen complex, not chondroitin monotherapy) n = 120

Finding: Skin elasticity improved +40% vs placebo (p<0.0001); histology showed reduced solar elastosis — but chondroitin cannot be isolated as the active agent in this multi-ingredient formula.

🟠 Limited quality ⚠️ Industry-funded Effect size: +40% skin elasticity (p<0.0001)

View on PubMed

Potential anti-ageing effect of chondroitin sulphate through skin regeneration

PMID: 32583476 2020 Cohort

Finding: CS increased keratinocyte and fibroblast proliferation, stimulated type I procollagen synthesis via ERK pathway, and promoted wound healing in aged skin — in vitro and animal models only, not human RCT.

🟠 Limited quality ⚠️ Industry-funded

View on PubMed

Drug Screening Implicates Chondroitin Sulfate as a Potential Longevity Pill

PMID: 35821992 2022 Narrative systematic review (longevity screening, not skin MA)

Finding: Narrative review concludes CS has favourable pharmacokinetics and tolerability, references RCT efficacy in joint disease — does not present original RCT data for skin aging outcomes.

🟠 Limited quality Academic

View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA

Cautious

FDA has no questions regarding Gnosis S.P.A.'s conclusion that chondroitin sulfate sodium is generally recognized as safe under its intended conditions of use. source↗

L4b EU EFSA

Against

L4c UK NHS

Against

GPs no longer prescribe chondroitin and glucosamine on the NHS because there's no strong evidence that they are effective as a treatment. NICE recommends that they should not routinely be offered on the NHS. source↗

L4d TW TFDA / 衛福部

Neutral

軟骨素在我國以及美國都不能取得藥品使用許可，祇能當作保健食品來販售。目前並沒有嚴謹的臨床試驗，可以證實軟骨素用於治療膝關節炎的療效。 source↗

L5a NIH Office of Dietary Supplements

Cautious

✓PMID 100% verifiedevery citation checked via NCBI Entrez

🔬3 PubMed studiesindependently re-checked by multiple sub-agents

engine_version: v1.0 claim_id: CLM-COND-skin-aging-INT-chondroitin-001 繁體中文版 →